Veloxis Pharmaceuticals A/S: Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017

Company Release no. 27/2017

To: NASDAQ Copenhagen A/S                                        Copenhagen,
Denmark, 31 December 2017 

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as
                              of 31 December 2017

                                        

Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the
Danish Statutory Order on Issuers' Disclosure Obligations, the total number of
shares and voting rights in the Company at the end of a calendar month in which
changes to the share capital have occurred. 

With reference to Company Release no. 24/2017 dated 01 December 2017 informing
of an increase in the share capital and the voting rights after exercise of
employee warrants, the table below provides the total number of shares and
voting rights in Veloxis as of 31 December 2017. 

            Date                 Total Number of Shares            Share
Capital           Total Number of Votes 

                           (nominal value of DKK 0.10 each) (nominal value in
DKK) 

     31 December 2017    1,712,438,531                    171,243,853.10       
         1,712,438,531 

For more information, please contact:

Craig Alexander Collard

President & CEO

Phone: [phone]

Email: [e-mail]

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical
company committed to improving the lives of transplant patients.  A Danish
company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis
Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North
Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus
extended-release tablets) based upon the Company's unique and patented delivery
technology, MeltDose, which is designed to enhance the absorption and
bioavailability of select orally administered drugs.  The Company is focused on
the direct commercialization of Envarsus XR in the U.S., expansion of
partnerships for markets around the world, and acquisition of assets utilized
in transplant patients and by adjacent medical specialties. Veloxis is listed
on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further
information, please visit www.veloxis.com.

Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=658488